Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Fentonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 8/20 | 0.67 |
| ▸ | CHRM5 known ✓ | P08912 | 6/20 | 0.64 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.64 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.64 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.64 |
| ▸ | BLM | P54132 | 4/20 | 0.69 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fentonium SCHEMBL30186606 | 1.00 | BLM (0.69) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Fentonium SCHEMBL24583 | 1.00 | BLM (0.69) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Fentonium SCHEMBL251444 | 0.99 | CHRM2 (0.68) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Fentonium SCHEMBL13724144 | 0.88 | CHRM1 (0.58) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Xenytropium SCHEMBL29371652 | 0.86 | BLM (0.71) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Xenytropium SCHEMBL24707 | 0.86 | BLM (0.71) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Xenytropium SCHEMBL30428452 | 0.85 | CHRM2 (0.71) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Xenytropium SCHEMBL29361010 | 0.85 | CHRM2 (0.71) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| SCHEMBL14507225 | 0.82 | CHRM2 (0.80) | BLMCHRM2PABPC1CYP2C19CHRM5 | |
| Methylatropine SCHEMBL30647266 | 0.82 | BLM (1.00) | BLMCHRM2PABPC1CYP2C19CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108430482-A | Control of cellular redox levels | 伊丽莎白·麦克纳 | 2018-08-21 | — | — | CN | claimed |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER LTD. (CH) | 2014-06-19 | — | — | US | claimed |
| EP-2691367-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | Hovione Inter Ltd. (CH) | 2014-02-05 | — | — | EP | claimed |
| CN-103502211-A | Electrophilic alkylating reagents, preparation and use thereof | HOVIONE FARMACIENCIA S A | 2014-01-08 | — | — | CN | claimed |
| WO-2012131286-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER. LTD (CH) | 2012-10-04 | — | — | WO | claimed |
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | OPRM1, OPRK1, OPRD1 | CHRM2 116/4885CHRM5 23/4885CHRM1 71/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CHRM2 4475/4885CHRM5 3509/4885CHRM1 4534/4885 |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | MGMT, MCL1, TOP2B | CHRM2 2607/4885CHRM5 3007/4885CHRM1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.